Plain-English translation of NCT06399263 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a research study testing , a psychedelic compound, as a treatment for anorexia nervosa in young adults aged 18–25 whose condition hasn't improved with standard care. The treatment includes two sessions where you receive the medication, along with multiple counseling sessions before and after to prepare you and help you process the experience. Your family members or close friends are also invited to participate in some sessions to support you through the process.
Anorexia nervosa is a serious eating disorder that is difficult to treat, and many people don't recover with standard therapy and medication alone. Researchers believe this medication might help by making your thinking more flexible, which could help break rigid thought patterns and behaviors that keep the eating disorder going.
You likely qualify if…
You likely don't qualify if…
You will attend multiple in-person sessions over several weeks. This includes three preparation meetings with a therapist, a first medication session (20mg dose), two integration sessions to discuss your experience, a second medication session (up to 25mg), and three final follow-up sessions. One or two family members will attend parts of some sessions and learn how to support you. You'll have your symptoms measured before and after treatment, and you must avoid certain medications, supplements, alcohol, and drugs during the study period.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States